BIOLINERX
Careers | Contact Us
search

Press Releases
July 25, 2011
BioLineRx  today announced that it has listed and begun trading American Depositary Receipts (ADRs) through BNY Mellon.
July 5, 2011
This clinical trial will be a first-in-human, single-site, double-blind, placebo controlled study to assess safety, tolerability and pharmacokinetics of BL-1021 in healthy volunteers.
July 5, 2011
BioLineRx plans to list its shares through American Depositary Receipts (ADRs), to be traded on the NASDAQ under ticker "BLRX.”
June 28, 2011
The CLARITY trial is expected to be conducted in 15 sites in Romania and 19 sites in India, on a total of 435 patients experiencing an acute exacerbation of schizophrenia.
June 27, 2011
"It has already demonstrated safety as well as its pharmacokinetic profile in earlier clinical trials, so we expect an accelerated development program "
May 17, 2011
"This new project, BL-7030,  holds great promise as a new targeted therapy for cancer'
May 11, 2011
Clinical Trial with Focus on Cognition on Track to Begin in June
April 4, 2011

Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application covering the BL-1020 drug and its use for the treatment of schizophrenia.

March 28, 2011
2010 revenue increased to NIS 113.2 million from NIS 63.9 million in 2009
February 27, 2011

The trial aims to evaluate the safety and effectiveness of BL-1040 for prevention of ventricular remodeling and congestive heart failure when administered following AMI.

271-280  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next